scholarly journals Prevalence of Thromboembolic Complications in COVID-19 Infection: A Systematic Review and Meta-Analysis

2021 ◽  
pp. 70-80
Author(s):  
Valeria Pergola ◽  
Honoria Ocagli ◽  
Giulia Lorenzoni ◽  
Danila Azzolina ◽  
Loira Leoni ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Thromboembolic Event ◽  
Event Rate ◽  
Meta Analysis ◽  
Diagnostic Testing ◽  
Venous Thromboembolic Event ◽  
Thromboembolic Complications ◽  
Analytical Estimate ◽  
Venous Thromboembolic ◽  
Registration Number

Introduction: The coronavirus disease (COVID-19) infection is proved to be involved in the onset of thromboembolism episodes. This study aims to evaluate the prevalence of thromboembolic complications in patients with COVID-19 from March until May 2020. Methods: A literature review was conducted in MEDLINE (via PubMed), Scopus, Embase, Cochrane, and CINHAL without any language and date of publication restriction (Prospero registration number CRD42020186925). The inclusion criteria were as following: 1) patients with diagnosis of COVID-19; 2) occurrence of thromboembolic event, and 3) patients older than 18 years of age. A multi-variable random effects model was computed accounting for correlations among outcomes by considering a heterogeneous compound symmetry covariance matrix. Results: Observational studies included 2,442 participants from 268 to 7,999 participants per study, 1,014 (41.52%) were male and 825 (33.78%) were female. The multi-variable pooled event rate of acute myocardial infarction was rare, estimated to be 0.03 (95% confidence interval [CI]: 0.00–0.07; p=0.23); this is also true for the meta-analytical estimate of disseminated intravascular disease which was 0.04 (95% CI: 0.00–0.08; p=0.03). Conversely, other events were found to be more frequent. Indeed, the pooled proportion of pulmonary embolism was 0.14 (95% CI: 0.08–0.20; p<0.001), while the venous thromboembolic event rate is 0.15 (95% CI: 0.09-0.30; p=0.04). The pooled intrahospital mortality rate was equal to 0.12 (95% CI: 0.08–0.16; p<0.001). Conclusions: Thromboembolic events, particularly venous thromboembolic event rate and pulmonary embolism, are a frequent complication in patients hospitalised with COVID-19. These findings suggest that the threshold for clinical suspicion should be low to trigger prompt diagnostic testing and that evaluation of therapeutic treatment should be considered in patients in intensive care units with COVID-19.

scholarly journals Lower Mortality and Morbidity With Low Molecular Weight Heparin for Venous Thromboembolic Event Prophylaxis in Spine Trauma

Neurosurgery ◽  
2019 ◽  
Vol 66 (Supplement_1) ◽  
Author(s):  
Emily K Chapman ◽  
Sean N Neifert ◽  
Robert J Rothrock ◽  
Frank Yuk ◽  
Ian T McNeill ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Thromboembolic Event ◽  
Venous Thromboembolic Event ◽  
Low Molecular Weight ◽  
Trauma Patients ◽  
Thromboembolic Complications ◽  
Spine Trauma ◽  
Cord Injury ◽  
Venous Thromboembolic

Abstract INTRODUCTION Up to 80% of spine trauma patients who do not receive thromboprophylaxis have a venous thromboembolic event (VTE) and pulmonary embolism (PE) is a major cause of death, yet national consensus on prophylactic regimens has not been reached. We compared the efficacy of low molecular weight heparin (LMWH) versus unfractionated heparin (UH) in decreasing poor outcomes in spine trauma patients. METHODS Isolated spine trauma cases in the American College of Surgeons Trauma Quality Improvement Program (TQIP) were queried using the Abbreviated Injury Scale (AIS). Patients who received LMWH were compared to UH on adjusted rates of in-hospital mortality, thromboembolic complications (DVT and PE), and total in-hospital complications. RESULTS UH patients had higher rates of spinal cord injury (32.26% vs 25.32%; P < .0001), altered mental status (6.26% vs 5.18%; P = .0005), hypotension on arrival (4.70% vs 4.11%; P = .03) and spinal fusions (29.52% vs 22.94%; P < .0001). LMWH patients had lower rates of mortality (OR: 0.74; 95% CI: 0.62-0.88; P = .0008), thromboembolic complications (OR: 0.75; 95% CI: 0.64-0.88; P = .0003), and total complications (OR: 0.89; 95% CI: 0.83-0.94; P = .0001). While nonfused patients had lower odds of death (OR: 0.35; 95% CI: 0.29-0.43; P < .0001), thromboembolic (OR: 0.71; 95% CI: 0.58-0.87; P = .001), and any complications (OR: 0.84; 95% CI: 0.78-0.91; P < .0001) when given LMWH, fused on LMWH had no improvement in these outcomes. CONCLUSION Spinal trauma patients who received LMWH were less likely to die, have thromboembolic complications and any complication compared to those who received UH. Further research, including randomized clinical trials, is necessary to investigate this potential benefit.

Anticancer drugs associated with venous thromboembolic event: Analysis of the WHO pharmacovigilance database.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 3094-3094
Author(s):  
Angélique DA Silva ◽  
Joachim Alexandre ◽  
Damien Laneelle ◽  
Marion Sassier ◽  
Basile Chrétien ◽  
...  
Keyword(s):  
Thromboembolic Event ◽  
Venous Thromboembolic Event ◽  
Population Characteristics ◽  
Event Analysis ◽  
Primary Tumor Site ◽  
New Therapies ◽  
Vein Thrombosis ◽  
Venous Thromboembolic ◽  
Registration Number ◽  
Pharmacovigilance Database

3094 Background: Venous thromboembolic event (VTE) is a frequent complication of cancer, as of some classical cancer therapy, like chemotherapy and surgery. The advent of new therapies such as immunotherapy and targeted therapies has meant that new therapies may be associated with VTE. Reliable data concerning the association between ADs and VTE are scarce. Methods: On March 1st, 2020 we utilized VigiBase (International pharmacovigilance database) and performed a disproportionality analysis using reporting odds ratios (ROR) to determine the association between the 206 FDA- or EMA-labeled ADs and VTE, defined as deep vein thrombosis and pulmonary embolism. RORs were adjusted (aRORs) on population characteristics including the cancer risk of VTE with the primary tumor site according to Khorana classification and metastatic status. Results: A total of 50,438 VTE cases associated with at least one AD were identified. Thirteen ADs were associated with higher reporting of VTE of which 2 represented new VTE associations not previously confirmed in the summary of product characteristics or literature including sipuleucel-t and megestrol. ADs more reported with VTE were lenalidomide (n:5,796), bevacizumab (n:2,780) and thalidomide (n:1,700). ADs associated-VTE occurred mainly during the first 6 months after AD initiation. Conclusions: Although cancer itself may generate VTE, we identified 13 ADs associated with VTE overreporting. Recognition of AD most likely to cause VTE can help raise practitioner awareness and lead to earlier diagnosis and treatment. Futures studies should include ADs in VTE risk evaluation and evaluate the management of VTE when recurrences occur under AD favoring VTE. ClinicalTrial registration number: NCT04696250.

scholarly journals Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis

Thorax ◽  
2021 ◽  
pp. thoraxjnl-2020-215383 ◽  
Author(s):  
Boun Kim Tan ◽  
Sabine Mainbourg ◽  
Arnaud Friggeri ◽  
Laurent Bertoletti ◽  
Marion Douplat ◽  
...  
Keyword(s):  
Observational Studies ◽  
Thromboembolic Event ◽  
Meta Analysis ◽  
Venous Thromboembolic Event ◽  
Vein Thrombosis ◽  
Coronary Syndrome ◽  
Specific Effects ◽  
Venous Thromboembolic ◽  
In Series ◽  
Deep Vein

BackgroundThe prevalence of venous thromboembolic event (VTE) and arterial thromboembolic event (ATE) thromboembolic events in patients with COVID-19 remains largely unknown.MethodsIn this meta-analysis, we systematically searched for observational studies describing the prevalence of VTE and ATE in COVID-19 up to 30 September 2020.ResultsWe analysed findings from 102 studies (64 503 patients). The frequency of COVID-19-related VTE was 14.7% (95% CI 12.1% to 17.6%, I2=94%; 56 studies; 16 507 patients). The overall prevalence rates of pulmonary embolism (PE) and leg deep vein thrombosis were 7.8% (95% CI 6.2% to 9.4%, I2=94%; 66 studies; 23 117 patients) and 11.2% (95% CI 8.4% to 14.3%, I2=95%; 48 studies; 13 824 patients), respectively. Few were isolated subsegmental PE. The VTE prevalence was significantly higher in intensive care unit (ICU) (23.2%, 95% CI 17.5% to 29.6%, I2=92%, vs 9.0%, 95% CI 6.9% to 11.4%, I2=95%; pinteraction<0.0001) and in series systematically screening patients compared with series testing symptomatic patients (25.2% vs 12.7%, pinteraction=0.04). The frequency rates of overall ATE, acute coronary syndrome, stroke and other ATE were 3.9% (95% CI 2.0% to to 3.0%, I2=96%; 16 studies; 7939 patients), 1.6% (95% CI 1.0% to 2.2%, I2=93%; 27 studies; 40 597 patients) and 0.9% (95% CI 0.5% to 1.5%, I2=84%; 17 studies; 20 139 patients), respectively. Metaregression and subgroup analyses failed to explain heterogeneity of overall ATE. High heterogeneity limited the value of estimates.ConclusionsPatients admitted in the ICU for severe COVID-19 had a high risk of VTE. Conversely, further studies are needed to determine the specific effects of COVID-19 on the risk of ATE or VTE in less severe forms of the disease.

scholarly journals Venous tromboembolic complications in stroke

2018 ◽  
pp. 70-77
Author(s):  
Екатерина Владимировна Силина ◽  
Е.Н. Кабаева ◽  
В.А. Ступин ◽  
А.А. Тяжельников ◽  
Т.Г. Синельникова ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Hemorrhagic Stroke ◽  
Clinical Laboratory ◽  
Disease Onset ◽  
Test Results ◽  
Thromboembolic Complications ◽  
Severe Stroke ◽  
Laboratory Markers ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

Актуальность работы обусловлена поиском путей улучшения результатов лечения больных инсультом. Цель исследования: выявить критерии прогноза риска развития венозных тромбозов, а также ключевые звенья патогенеза тромбоэмболических осложнений у пациентов с острым инсультом. Материалы и методы: в проспективное исследование включено 145 больных с инсультом (104 с ишемическим (ИИ) и 41 с геморрагическим (ГИ)), госпитализированных в отделение нейрореанимации в период 3,5-24 часа от начала заболевания и имеющих на момент включения в исследование различную степень депрессии сознания (тяжелая степень инсульта). Пациентам проводилась терапия в соответствии со стандартами оказания медицинской помощи, согласно которым всем пациентам назначали антикоагулянтную терапию (АКТ). Выполняемый в динамике стандартный клинико-диагностический и лабораторный мониторинг был дополнен тестом «Тромбодинамика». Результаты: у 95% пациентов с инсультом зарегистрированы различные факторы риска венозных тромбоэмболических осложнений (ВТЭО). Тромбоэмболия легочной артерии (ТЭЛА) развилась в 24% случаев, преимущественно на 2-3 неделе, в среднем через 6 дней после отмены АКТ. Описана динамика и признаки дисбаланса в системе гемостаза у больных инсультом, нараставшие после отмены АКТ. Показано, что стандартные методы исследования системы гемостаза по сравнению с прямым методом менее информативны для выявления ВТЭО и оценки эффективности АКТ. Вероятность развития ВТЭО прямо пропорциональна скорости смены состояния гиперкоагуляции состоянием гипокоагуляции. При этом состояние фоновой гиперкоагуляции не коррелирует с развитием ВТЭО. Корреляционный анализ изменений в системе гемостаза с динамикой клинико-лабораторных маркеров у больных с тяжелым инсультом выявил закономерные изменения показателей коагуляционного гемостаза в условиях реализации разных схем стандартной АКТ. Эти схемы были сопоставимы по содержанию при развитии как ВТЭО и ТЭЛА, так и геморрагических осложнений. Вывод: К больным инсультом необходим персонализированный подход при динамическом мониторировании гемостаза и назначении антикоагулянтной терапии. This work was warranted by the need to improve results in the treatment of stroke. The aim of this study was to identify criteria for predicting the risk of venous thrombosis and to elucidate the pathogenesis of thromboembolic complications in patients with acute stroke. Materials and methods. This prospective study included 145 patients (104 patients with ischemic stroke and 41 patients (28.3%) with hemorrhagic stroke). All patients were hospitalized to the neuroresuscitation unit within 3.5 to 24 hours of the disease onset at different stages of consciousness impairment. The patients received anticoagulant therapy (ACT) according to current healthcare standards. Standard clinical diagnostic and laboratory monitoring was supplemented with a Thrombodynamics test. Results. Risk factors for venous thromboembolic events (VTE) were observed in 95% of patients. Pulmonary embolism developed in 24% of cases mostly during weeks 2-3, generally at 6 days of ACT withdrawal. Hemostatic changes and disbalance progressed after the ACT withdrawal. Standard methods of studying hemostasis were shown to be less informative in detecting VTE and evaluating ACT efficacy than the thermodynamics method. The probability of VTE was directly proportional to the velocity of hypercoagulation transformation into hypocoagulation. In this process, the background hypocoagulation was not correlated with the development of VTE. Analysis of correlations of hemostasis changes with changes in clinical-laboratory markers identified relationships of changes in coagulation hemostasis with different standard ACT programs. VTE, pulmonary embolism, and hemorrhagic complications developed in association with administration of comparable ACT programs to patients with severe stroke.

Thrombosis and the Antiphospholipid Syndrome

Hematology ◽  
2005 ◽  
Vol 2005 (1) ◽  
pp. 462-468 ◽  
Author(s):  
Thomas L. Ortel
Keyword(s):  
Risk Factors ◽  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Thromboembolic Event ◽  
Randomized Clinical Trials ◽  
Venous Thromboembolic Event ◽  
Thromboembolic Events ◽  
Additional Risk ◽  
Initial Event ◽  
Venous Thromboembolic

Abstract The antiphospholipid syndrome is an antibody-mediated hypercoagulable state characterized by recurrent venous and arterial thromboembolic events. Several studies have determined that the frequency of antiphospholipid syndrome in patients presenting with a venous thromboembolic event is between 4% and 14%. Because of the high risk for recurrent thromboembolism in these patients, current recommendations suggest a longer, potentially lifelong, course of antithrombotic therapy following an initial event. Although most authorities agree on an extended course of therapy, considerable controversy surrounds the optimal target therapeutic INR for patients with antiphospholipid syndrome. For an initial venous thromboembolic event, a target INR of 2.0 to 3.0 is supported by two prospective, randomized clinical trials. In contrast, relatively limited data exist for an initial arterial thromboembolic event in patients who have the antiphospholipid syndrome, and therapeutic recommendations range from aspirin to warfarin with a high target INR. Recurrent thromboembolic events can be extremely difficult to treat, and some patients may benefit from the addition of immunosuppressive therapies. Importantly, as many as 50% of the initial thromboembolic events sustained by patients with antiphospholipid antibodies occur in the setting of additional, coincident prothrombotic risk factors, indicating the importance of addressing any additional risk factors, such as hypercholesterolemia, in these patients. Prospective studies are needed to address the role of thromboprophylactic strategies in asymptomatic individuals with antiphospholipid antibodies in the absence of additional risk factors.

scholarly journals Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data

2017 ◽  
Vol 1 (26) ◽  
pp. 2637-2642 ◽  
Author(s):  
Matteo Rota ◽  
Paolo A. Cortesi ◽  
Roberto Crea ◽  
Alessandro Gringeri ◽  
Lorenzo G. Mantovani
Keyword(s):  
Thromboembolic Event ◽  
Event Rate ◽  
Meta Analysis ◽  
Published Data ◽  
Key Points ◽  
Low Incidence

Key Points AICC has been used since 1977 to control bleeding in patients with hemophilia with inhibitors. AICC is associated with a low incidence of TEEs, especially when administered prophylactically.

scholarly journals Association of the Risk of a Venous Thromboembolic Event in Emergency vs Elective General Surgery

JAMA Surgery ◽  
2020 ◽  
Vol 155 (6) ◽  
pp. 503 ◽  
Author(s):  
Samuel W. Ross ◽  
Kali M. Kuhlenschmidt ◽  
John C. Kubasiak ◽  
Lindsey E. Mossler ◽  
Luis R. Taveras ◽  
...  
Keyword(s):  
General Surgery ◽  
Thromboembolic Event ◽  
Venous Thromboembolic Event ◽  
Venous Thromboembolic

Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 119 (03) ◽  
pp. 479-489 ◽  
Author(s):  
Lisa Duffett ◽  
Clive Kearon ◽  
Marc Rodger ◽  
Marc Carrier
Keyword(s):  
Systematic Review ◽  
Primary Outcome ◽  
Event Rate ◽  
Meta Analysis ◽  
Vein Thrombosis ◽  
Superficial Vein Thrombosis ◽  
Venous Thromboembolic ◽  
Event Rates ◽  
Deep Vein

Background The optimal first line treatment for patients with isolated superficial venous thrombosis (SVT) of the lower extremity is unknown. Objective This article reports estimates of the rate of venous thromboembolic complications among patients with SVT according to treatment. Materials and Methods A systematic review and meta-analysis was performed using unrestricted searches of electronic databases. Reported events were transformed to event per 100 patient-years of follow-up and a random effects model was used to calculate pooled rates according to pre-specified treatment categories. The primary outcome was the occurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE) during the study follow-up period. Results Seventeen articles, including 6,862 patients, were included in the meta-analysis. Fondaparinux had the lowest event rate with 1.4 events per 100 patient-years of follow-up (95% confidence interval [CI], 0.5–2.8, I 2 = 18%). Pooled event rates for DVT or PE ranged from 9.3 to 16.6 events per 100 patient-years across other treatment categories, and the pooled event rate for no treatment/placebo was 10.5 events per 100 patient-years (95% CI, 3.0–22.0). Major bleeding was low and similar across all treatment categories. Heterogeneity was moderate to high for most pooled estimates. Conclusion While pooled event rates suggest that fondaparinux achieves the lowest rate of DVT or PE, low-quality evidence for other treatments prevents firm conclusions about the optimal treatment for SVT.

Sign in / Sign up

Export Citation Format

Share Document